Mirum Pharmaceuticals (NASDAQ:MIRM) Downgraded to Hold Rating by Wall Street Zen

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) was downgraded by stock analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a report released on Sunday.

A number of other equities analysts also recently commented on the company. Raymond James Financial reissued a "strong-buy" rating on shares of Mirum Pharmaceuticals in a research report on Tuesday, May 13th. HC Wainwright reissued a "buy" rating and set a $73.00 price objective on shares of Mirum Pharmaceuticals in a research report on Monday, May 19th. Finally, JMP Securities boosted their price objective on Mirum Pharmaceuticals from $74.00 to $76.00 and gave the stock a "market outperform" rating in a research report on Friday, May 9th. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $65.50.

Mirum Pharmaceuticals Trading Up 5.7%

NASDAQ MIRM traded up $2.87 during trading on Friday, hitting $53.14. The stock had a trading volume of 221,386 shares, compared to its average volume of 475,106. The company has a market capitalization of $2.63 billion, a PE ratio of -33.01 and a beta of 0.97. The company has a quick ratio of 3.04, a current ratio of 3.22 and a debt-to-equity ratio of 1.32. The firm has a 50 day moving average price of $46.79 and a 200 day moving average price of $45.65. Mirum Pharmaceuticals has a twelve month low of $35.63 and a twelve month high of $54.23.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.05. The business had revenue of $111.59 million for the quarter, compared to analysts' expectations of $98.47 million. Mirum Pharmaceuticals had a negative return on equity of 33.63% and a negative net margin of 20.39%. The company's revenue for the quarter was up 61.2% compared to the same quarter last year. During the same period last year, the firm earned ($0.54) earnings per share. As a group, equities research analysts forecast that Mirum Pharmaceuticals will post -1.43 earnings per share for the current year.

Insiders Place Their Bets

In other Mirum Pharmaceuticals news, SVP Jolanda Howe sold 564 shares of the business's stock in a transaction that occurred on Wednesday, July 2nd. The stock was sold at an average price of $48.25, for a total value of $27,213.00. Following the completion of the sale, the senior vice president owned 2,903 shares in the company, valued at approximately $140,069.75. The trade was a 16.27% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 22.87% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Mirum Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. CWM LLC raised its stake in shares of Mirum Pharmaceuticals by 259.4% during the first quarter. CWM LLC now owns 593 shares of the company's stock worth $27,000 after purchasing an additional 428 shares during the last quarter. Jones Financial Companies Lllp raised its stake in shares of Mirum Pharmaceuticals by 100.0% during the fourth quarter. Jones Financial Companies Lllp now owns 714 shares of the company's stock worth $30,000 after purchasing an additional 357 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Mirum Pharmaceuticals during the fourth quarter worth approximately $35,000. Comerica Bank raised its stake in shares of Mirum Pharmaceuticals by 45.1% during the first quarter. Comerica Bank now owns 895 shares of the company's stock worth $40,000 after purchasing an additional 278 shares during the last quarter. Finally, GF Fund Management CO. LTD. purchased a new stake in shares of Mirum Pharmaceuticals during the fourth quarter worth approximately $42,000.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.